If you have unexplained yellowing of your skin or eyes, dark urine, sudden nausea, or a recent blood test showing your liver enzymes are sharply elevated, this test answers a specific question: is hepatitis A virus the cause? Anti-HAV IgM (the IgM-class antibody your body makes against hepatitis A virus) appears around the time symptoms start and is the standard way to confirm a recent infection.
Hepatitis A is usually self-limited, meaning it resolves on its own without lasting liver damage. But during the acute illness it can hit hard, and knowing whether your symptoms come from this virus, another viral hepatitis, a medication reaction, or an autoimmune cause changes what you do next. This is the test that pins it down.
Your immune system produces different classes of antibodies in a predictable order during an infection. IgM (immunoglobulin M) is the early-response class, appearing roughly when symptoms begin. IgG (immunoglobulin G) appears later and sticks around for life, marking past infection or successful vaccination. Anti-HAV IgM signals a recent infection. Anti-HAV IgG signals immunity, whether from a past infection or a vaccine.
A clearly positive Anti-HAV IgM test, combined with very high liver enzymes and symptoms like jaundice, is strong evidence of acute hepatitis A. In a UK study of 7,661 samples, every confirmed acute case had an Anti-HAV IgM index above 4.0, with an average of 9.4 and an average peak ALT (alanine aminotransferase, a liver enzyme) of 1,920 U/L. Low-level or borderline positive results, on the other hand, were usually something else: roughly 64% of low-level positives turned out to have alternative diagnoses, and no acute hepatitis A was confirmed among low or equivocal results when full clinical data were available.
Anti-HAV IgM does not vanish quickly. After acute infection, levels can persist anywhere from less than 30 days to more than 420 days. Most people become negative by around 120 days, but roughly 13.5% remain positive for over 200 days. This means a positive IgM result, on its own, does not always mean the infection is happening right now. Pairing the antibody result with liver enzymes, symptoms, and timing is what makes the diagnosis solid.
Hepatitis A is generally an acute, self-limited illness. It does not cause chronic infection, cirrhosis, or liver cancer the way hepatitis B and C can. Population studies that combine total Anti-HAV antibodies with IgM testing track lifetime exposure but do not link a positive IgM result to chronic liver complications. The clinical importance of confirming the diagnosis is mostly about three things: ruling out other causes that need different treatment, supporting recovery, and protecting people you live or work with from getting infected.
Anti-HAV IgM is reported as a qualitative result (reactive or non-reactive) along with a numeric value. The numeric scale depends on the analyzer your lab uses. There is no universal cutoff. Different platforms use different units (signal-to-cutoff ratios on some, cutoff index values on others), and head-to-head studies show meaningful disagreement between assays. The cutoffs below come from a real-world clinical audit using one common platform and are illustrative, not universal targets. Your lab will likely report different numbers.
| Result Tier | Anti-HAV IgM Value (Architect platform) | What It Suggests |
|---|---|---|
| Non-reactive | Below the manufacturer's cutoff | No evidence of recent hepatitis A infection |
| Low-level reactive | Just above the cutoff, below 4.0 | Frequently a false positive; alternative diagnoses are common |
| Clearly reactive | Above 4.0 (mean 9.4 in confirmed cases) | Consistent with acute hepatitis A, especially with high liver enzymes and symptoms |
Compare your results within the same lab over time, since cross-platform variability is substantial. A reactive result without symptoms or liver enzyme changes deserves a second look before it drives any decision.
In a Korean study of 136 patients with acute severe hepatitis, Anti-HAV IgM caught roughly 79 to 91 out of every 100 true acute hepatitis A cases (sensitivity), depending on how borderline results were counted. Specificity was 100%, meaning a clear positive in the right clinical context is highly trustworthy. The main miss is the early window before antibodies have risen. HAV RNA PCR (a test that detects the virus's genetic material directly) caught around 81 out of 100 cases and identified every patient whose Anti-HAV IgM was negative or borderline early in their illness.
What this means for you: if symptoms started very recently and Anti-HAV IgM is negative or unclear, a follow-up test, HAV RNA PCR, or repeat serology a few days later can clarify the picture. A clearly positive IgM with sky-high liver enzymes is generally definitive on its own.
Anti-HAV IgM is not a marker you trend over years to manage health. It is an answer to a specific question at a specific moment: is this acute illness caused by hepatitis A? You order it once when there is reason to suspect the infection. If positive and clearly elevated alongside high liver enzymes and symptoms, the diagnosis is confirmed and the course is supportive care: rest, hydration, avoiding alcohol and unnecessary medications that stress the liver, and notifying close contacts so they can be vaccinated or given immune globulin.
If your result is borderline, ambiguous, or does not fit your clinical picture, the next step is not to assume the worst or dismiss it. Repeat the test in a few days, add HAV RNA PCR if the timing is early, and check Anti-HAV IgG to see if you have past immunity. A hepatologist or infectious disease specialist is worth involving when results conflict with symptoms, when liver function is severely impaired, or when an alternative cause like drug-induced or autoimmune hepatitis needs to be ruled out.
Once you have recovered, repeat IgM testing serves no preventive purpose. The longer-term marker that matters is Anti-HAV IgG, which confirms you are now immune to future hepatitis A infections.
Hepatitis A IgM is best interpreted alongside these tests.